<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249115</url>
  </required_header>
  <id_info>
    <org_study_id>NP-SK-008</org_study_id>
    <nct_id>NCT04249115</nct_id>
  </id_info>
  <brief_title>Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study</brief_title>
  <official_title>Prospective, Open-Label, Multi-Center, Non-Significant Risk Study of Nano-Pulse Stimulation™ (NPS™) Technology in Healthy Adults With Seborrheic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulse Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulse Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS)&#xD;
      energy settings for lesion clearance of Seborrheic Keratosis (SKs) from off-facial areas of&#xD;
      healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Evaluate lesion clearance rate of SKs in off-face locations post-treatment versus&#xD;
           baseline using multiple sized treatment tips with microneedles.&#xD;
&#xD;
        -  Evaluate the clearance of the treated SKs using multiple energy settings at various time&#xD;
           points initial procedure, compared baseline.&#xD;
&#xD;
        -  Evaluate skin effects and adverse event rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance Rate of SK Lesions</measure>
    <time_frame>90 days post-last treatment</time_frame>
    <description>Degree of Clearance of SK lesion treated with NPS as rated by investigators.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Lesion Skin</condition>
  <condition>Seborrheic Keratosis</condition>
  <condition>Skin Lesion</condition>
  <condition>Benign Skin Tumor</condition>
  <arm_group>
    <arm_group_label>Nano-Pulse Stimulation (NPS) Treated Lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nano-Pulse Stimulation of targeted lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nano-Pulse Stimulation (NPS)</intervention_name>
    <description>Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.</description>
    <arm_group_label>Nano-Pulse Stimulation (NPS) Treated Lesion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female between 21 and 75 years of age&#xD;
&#xD;
          -  Voluntary, written informed consent to participate in this clinical investigation and&#xD;
             from whom consent has been obtained&#xD;
&#xD;
          -  Understanding of the clinical investigation, agree to cooperate with the&#xD;
             investigational procedures and willing to return for all the required follow-up visits&#xD;
&#xD;
          -  Understands that SKs are to be treated in a single treatment session and is aware that&#xD;
             they may receive a second treatment&#xD;
&#xD;
          -  Must be able to visit clinic site at 7-, 30-, 60-, and 90-days post-primary treatment&#xD;
             of SK lesion and at retreatment&#xD;
&#xD;
          -  Clinical diagnosis of stable, clinically typical Seborrheic Keratosis&#xD;
&#xD;
          -  Minimum of two SK lesions&#xD;
&#xD;
          -  SKs must be no greater than 2mm in height and not exceed 10mm x 10mm at their largest&#xD;
             point&#xD;
&#xD;
          -  Undergo all study procedures including consent for global photographs of the SK study&#xD;
             sites&#xD;
&#xD;
          -  Agrees to refrain from using all other SK lesion removal products or treatments&#xD;
             (topical medication including over-the-counter medications) during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Implantable electronic devices (i.e., automatic defibrillator)&#xD;
&#xD;
          -  Active infection or history of infection in designated test area within 90 days prior&#xD;
             to first treatment&#xD;
&#xD;
          -  Not willing or able to sign the Informed Consent&#xD;
&#xD;
          -  Known to be immune-compromised&#xD;
&#xD;
          -  Known to be keloid producer&#xD;
&#xD;
          -  Taking blood thinning medications&#xD;
&#xD;
          -  Insulin dependent, Type I diabetics&#xD;
&#xD;
          -  Allergies to Lidocaine or Lidocaine-like products&#xD;
&#xD;
          -  Employed by the sponsor, clinic site, or entity associated with the conduct of the&#xD;
             study&#xD;
&#xD;
          -  Family member of someone employed by the sponsor, clinic site, or entity associated&#xD;
             with the conduct of the study&#xD;
&#xD;
          -  Have any condition or situation which, in the Investigator's opinion, puts the subject&#xD;
             at significant risk, could confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study&#xD;
&#xD;
          -  Prior inability to complete required study visits during treatment period.&#xD;
&#xD;
          -  Use of any other investigational drug, therapy, or device within the past 30 days of&#xD;
             enrollment or concurrent participation in another research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Nuccitelli, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulse Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clear Dermatology &amp; Aesthetics Center / InvestigateMD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Dermatology Specialists</name>
      <address>
        <city>Edwards</city>
        <state>Colorado</state>
        <zip>81632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKIN Associates of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cosmetic Surgery and Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zel Skin &amp; Laser Specialists</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Seborrheic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

